Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study
Makaleler > Tam Makale · 2026
Yazarlar: Taha Koray Sahin, Fatih Kemik, Harun Muglu, Bedriye Acikgöz Yildiz, Sedat Biter, Salih Tunbekici, Ahmet Oruc, Ali Kaan Guren, Kerim Kaban, Halil Goksel Guzel, Cihan Erol, Musa Baris Aykan, Bahadir Koylu, Omer Burak Ekinci, Ilknur Deliktas Onur, Ali Kalem, Oguz Altunok, Mustafa Seyyar, Bunyamin Guney, Orhun Akdogan, Rashad Ismayilov, Fadime Sinem Ardic, Melike Yazici, Nargiz Majidova, Sema Turker, Ece Esin, Devrim Cabuk, Hatime Arzu Yasar, Arzu Oguz, Ozan Yazici, Riza Umar Gursu, Mesut Yılmaz, Havva Yesil Cinkir, Ozturk Ates, Emir Celik, Nuri Karadurmus, Umut Demirci, Banu Ozturk, Nil Molinas Mandel, Ibrahim Vedat Bayoglu, Murat Araz, Erdem GÖKER, Ertugrul Bayram, Dilek Erdem, Fatih Selcukbiricik, Gul Basaran, Ahmet Sezer, Gamze Gokoz Dogu, Yasemin Kemal, Ahmet Bilici, Seyda Gunduz, Deniz Can Guven, Sercan Aksoy
Therapeutic Advances in Medical Oncology, Uluslararası, Wos, 2026, cilt 18
DOI: 10.1177/17588359261430583
Özet
Background: Trastuzumab deruxtecan (T-DXd) has transformed the treatment landscape of human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC), with significant improvements in survival reported in clinical trials. However, limited data exist regarding its performance in real-world settings, particularly in lower-middle-income countries (LMICs). Objectives: To evaluate the real-world effectiveness and safety of T-DXd in patients with HER2+ mBC in Türkiye. Design: A multicenter retrospective cohort study. Methods: This multicenter, retrospective cohort study, conducted by the Turkish Oncology Group, evaluated the real-world outcomes and tolerability of T-DXd in patients with HER2+ mBC across 27 oncology centers in Türkiye. The primary endpoints were real-world progression-free survival (rwPFS) and overall survival (rwOS). Secondary endpoints included response rate, safety (with adverse events (AEs) graded according to CTCAE v5.0), and evaluation of the first post-T-DXd treatments. Results: A total of 269 patients were included. The median age was 49 years (interquartile range: 42–59), and the median follow-up was 12.9 months. The median rwPFS was 17.9 months (95% confidence interval: 13.3–22.5), and the median rwOS was 35.7 months (95% confidence interval: 27.8–43.6). The objective response rate was 71.4%, and the disease control rate was 95.2%. Patients receiving T-DXd in the second line experienced significantly longer rwPFS compared with those treated in later lines ( p < 0.001). Treatment-related AEs of any grade occurred in 68.4% of patients. Interstitial lung disease was reported in 21 patients (7.8%), with 4 cases being grade ⩾3. Conclusion: In this large national real-world cohort from an LMIC, T-DXd demonstrated robust antitumor activity and a manageable safety profile in patients with HER2+ mBC. These findings are consistent with prior clinical trial data and support the applicability of T-DXd in broader clinical settings.